Final results of a multicenter phase II study of irinotecan (CPT-11) in patients (pts) with advanced hepatocellular carcinoma (HCC)
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4180-4180
Keyword(s):
Phase Ii
◽
2016 ◽
Vol 77
(2)
◽
pp. 243-250
◽
2018 ◽
Vol 48
(4)
◽
pp. 317-321
◽